Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Mortality rates among United States veterans with sarcoidosis have been rising since 2004, most notably in men, according to study findings published in Chest. Investigators studied the trends in ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

Sarcoidosis is an inflammatory disease that can affect any organ in the body, although it is most commonly found in the lungs and lymph nodes. The condition is characterized by the formation of ...

These cells develop most commonly in the lungs and lymph nodes, and though the disease is typically very manageable, it can lead to death in rare cases. Dennis' father had sarcoidosis and died ...

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index. This recent study highlights ...

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in one or more organs of the body. When left unchecked, chronic inflammation caused by granulomas can lead to ...

The study enrolled 107 patients with pulmonary sarcoidosis considered to have chronic, active disease not well-controlled despite available therapeutic options. Patients in the study received a ...

It is a rare disease that causes lumps of inflammatory cells to form in the lungs and other organs, leading to tissue damage and organ dysfunction. Shares of Roivant fell 1.3% in premarket trading.

chronic obstructive pulmonary disease, pulmonary hypertension, cystic fibrosis, bronchiectasis, and sarcoidosis. Meet the experts that make up our lung transplant team.

Dec 3 (Reuters) - Roivant (ROIV.O), opens new tab will discontinue the development of its drug for a rare lung disease after it failed to show treatment benefits in patients in a mid-stage trial.